# Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension

Study · id `cardio:ct-nct04518293` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04518293](<https://clinicaltrials.gov/study/NCT04518293>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04518293

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1385 participants.

## Technical summary

Registry record NCT04518293. Randomized; quadruple masking; primary purpose treatment. Start 2021-07-09 (actual); primary completion 2023-08-11 (actual). Results posted on 2025-06-03.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1385 participants (enrolled count; ClinicalTrials.gov record NCT04518293, source copy `cardio:ctgov-nct04518293-2025-06-03`, retrieved 2026-10-26)
- Started: 2021-07-09 (actual) (ClinicalTrials.gov record NCT04518293, source copy `cardio:ctgov-nct04518293-2025-06-03`, retrieved 2026-10-26)
- Primary completion: 2023-08-11 (actual) (ClinicalTrials.gov record NCT04518293, source copy `cardio:ctgov-nct04518293-2025-06-03`, retrieved 2026-10-26)
- Completion: 2023-09-01 (actual) (ClinicalTrials.gov record NCT04518293, source copy `cardio:ctgov-nct04518293-2025-06-03`, retrieved 2026-10-26)
- Results first posted: 2025-06-03 (ClinicalTrials.gov record NCT04518293, source copy `cardio:ctgov-nct04518293-2025-06-03`, retrieved 2026-10-26)
- Countries: United States; Australia; Czechia; New Zealand; Poland; Sri Lanka; United Kingdom (ClinicalTrials.gov record NCT04518293, source copy `cardio:ctgov-nct04518293-2025-06-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04518293-2025-06-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension
- Acronym: GMRx2\_ACT
- Condition: Hypertension
- Intervention (Drug): Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
- Intervention (Drug): telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg
- Intervention (Drug): Telmisartan 20 mg/amlodipine 2.5 mg
- Intervention (Drug): telmisartan 40 mg/amlodipine 5 mg
- Intervention (Drug): Telmisartan 20 mg/indapamide 1.25 mg
- Intervention (Drug): telmisartan 40 mg/indapamide 2.5 mg
- Intervention (Drug): Amlodipine 2.5 mg/indapamide 1.25 mg
- Intervention (Drug): amlodipine 5 mg/indapamide 2.5 mg
- Lead sponsor: George Medicines PTY Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial (`cardio:pubmed-39426836`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 0513b47ea4b70389daf379fdb4a63ebef536ca91396e57b70f81f40a50c0388d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
